The role of brigatinib in crizotinib-resistant non-small cell lung cancer
Laura Mezquita, David Planchard Medical Oncology Department, Gustave Roussy, Villejuif, France Abstract: Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of relapse...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2018-01-01
|
| Serie: | Cancer Management and Research |
| Soggetti: | |
| Accesso online: | https://www.dovepress.com/the-role-of-brigatinib-in-crizotinib-resistant-non-small-cell-lung-can-peer-reviewed-article-CMAR |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|